Cholinergic basal forebrain neurons are a collection of acetylcholine-producing neurons located in the basal forebrain that provide the primary cholinergic innervation to the entire cerebral cortex and hippocampus. These neurons are essential for attention, arousal, learning, and memory. Their degeneration is a hallmark of Alzheimer's disease and contributes to cognitive decline across multiple neurodegenerative disorders, making them a key therapeutic target. [1]
| Taxonomy | ID | Name / Label | [2]
|----------|----|---------------| [3]
| Cell Ontology (CL) | CL:0000108 | cholinergic neuron | [4]
The primary population of cholinergic basal forebrain neurons resides in the nucleus basalis of Meynert (NBM), also called Ch4: [5]
The basal forebrain cholinergic system comprises four main groups (Ch1-Ch4): [7]
| Group | Nucleus | Primary Projection Target | [8]
|-------|---------|--------------------------| [9]
| Ch1 | Medial septum | Hippocampus | [10]
| Ch2 | Vertical diagonal band | Hippocampus | [11]
| Ch3 | Horizontal diagonal band | Olfactory bulb |
| Ch4 | Nucleus basalis | Neocortex[12] |
Cholinergic basal forebrain neurons are characterized by:
NBM cholinergic neurons project throughout cortex:
The projections are topographically organized:
Ch1/Ch2 neurons (medial septum) provide:
Some basal forebrain neurons co-release:
Cholinergic basal forebrain neurons:
Cholinergic signaling:
Basal forebrain cholinergic neurons:
Cholinergic basal forebrain neurons are severely affected in AD:
Pathological changes:
Functional consequences:
Molecular vulnerability factors:
Cholinergic deficits contribute to:
Marked cholinergic deficits:
NBM degeneration contributes to:
First-line treatment for cognitive symptoms:
Efficacy:
Under investigation:
NGF-based approaches:
NBM-DBS being investigated for:
Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia. Science. 1982. ↩︎
Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease. International Journal of Developmental Neuroscience. 2009. ↩︎
Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behavioural Brain Research. 2011. ↩︎
Tiraboschi P, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology. 2000. ↩︎
Warren NM, Piggott MA, Lees AJ, Perry EK. Basal forebrain cholinergic system. Brain. 2007. ↩︎
1 ↩︎
Racchi M, Mazzucchelli M, Porrello E, Lanza C, Govoni S. Acetylcholinesterase inhibitors. Pharmacological Research. 2004. ↩︎
Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2006. ↩︎
Haydar SN, Dunlop J. Neuronal nicotinic acetylcholine receptors. Pharmacology Biochemistry and Behavior. 2010. ↩︎
Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy. JAMA Neurology. 2015. ↩︎
Kuhn J, Hardenacke K, Lenartz D, et al. Deep brain stimulation of the nucleus basalis of Meynert. Journal of Alzheimer's Disease. 2015. ↩︎
2 ↩︎
3 ↩︎
4 ↩︎
5 ↩︎
6 ↩︎
7 ↩︎
8 ↩︎
9 ↩︎
10 ↩︎
11 ↩︎
12 ↩︎
13 ↩︎
14 ↩︎
15 ↩︎
16 ↩︎
17 ↩︎
18 ↩︎
19 ↩︎
20 ↩︎
21 ↩︎